Crinetics Pharmaceuticals, Inc. Financial Ratios
CRNX / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-46.9%
Profit Margin
-6046.2%
Net Income / Revenue
Asset Turnover
0.01
Revenue / Total Assets
Equity Multiplier
1.14
Total Assets / Equity
Composite: -46.9% (reported: -46.9%)
Profitability
Liquidity
Current Ratio
12.32
Quick Ratio
12.30
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.01
Inventory Turnover
0.53
Days Sales Outstanding
28 days
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
Earnings Quality
Accrual Ratio
-6.8%
-2.1pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.